



## King's Research Portal

DOI:

[10.1016/j.thromres.2018.06.016](https://doi.org/10.1016/j.thromres.2018.06.016)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Byrne, R., Brown, A., Patel, J. P., Czuprynska, J., Roberts, L. N., Patel, R. K., & Arya, R. (2018). Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes: A note of caution. *Thrombosis Research*. <https://doi.org/10.1016/j.thromres.2018.06.016>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## Accepted Manuscript

Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – A note of caution

Rosalind Byrne, Alison Brown, Jignesh P. Patel, Julia Czuprynska, Lara N. Roberts, Raj K. Patel, Roopen Arya



PII: S0049-3848(18)30390-6  
DOI: doi:[10.1016/j.thromres.2018.06.016](https://doi.org/10.1016/j.thromres.2018.06.016)  
Reference: TR 7070  
To appear in: *Thrombosis Research*  
Received date: 16 November 2017  
Revised date: 15 June 2018  
Accepted date: 18 June 2018

Please cite this article as: Rosalind Byrne, Alison Brown, Jignesh P. Patel, Julia Czuprynska, Lara N. Roberts, Raj K. Patel, Roopen Arya , Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – A note of caution. Tr (2018), doi:[10.1016/j.thromres.2018.06.016](https://doi.org/10.1016/j.thromres.2018.06.016)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – a note of caution**

Rosalind Byrne, Alison Brown, Jignesh P. Patel, Julia Czuprynska, Lara N. Roberts, Raj K. Patel,  
Roopen Arya

Rivaroxaban is a direct factor Xa inhibitor currently licensed for the acute treatment and prevention of venous thromboembolism and for the prevention of stroke in the context of atrial fibrillation (AF). Rivaroxaban is rapidly absorbed with maximum concentrations reported around 2 - 4 hours post ingestion. Oral bioavailability is high (80 - 100%) for the 2.5mg and 10 mg tablet dose under fasting conditions or with food. The 20mg dose of rivaroxaban has reduced bioavailability of 66%, under fasting conditions, increasing to near 100% when taken with food [SPC, 2016]. Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in area-under the concentration-time-curve (AUC) and C<sub>max</sub> compared to tablet is reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon [SPC, 2016]. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure. For patients unable to ingest whole tablets, rivaroxaban may be given through a gastric tube after confirmation of the correct placement of the tube. It is suggested that the crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water. The dose of rivaroxaban should then be immediately followed by enteral feeding [Moore *et al.*, 2014; SPC, 2016].

We report our experience of administering rivaroxaban via a PEG tube in three patients requiring oral anticoagulation therapy, following a cardioembolic stroke (table 1). A direct oral anticoagulant was selected over warfarin in order to reduce the need for regular INR testing in the community and as part of a local initiative to decrease district nursing workload.

Table 1: Details of the 3 cases who had rivaroxaban administered via a PEG tube, for the secondary prevention of stroke in the context of AF

	Case 1	Case 2	Case 3
<b>Gender</b>	M	M	M
<b>Age</b>	78	85	82
<b>CHA<sub>2</sub>DS<sub>2</sub>Vasc score</b>	5	5	5
<b>Stroke</b>	Left vertebral artery occlusion	left centrum semiovale infarct	Left middle cerebral artery infarct
<b>Dose</b>	20mg daily	20mg daily	20mg daily
<b>CrCL (mL/min)*</b>	103	42	62
<b>Timing of feed</b>	PEG feed given 12am to 5pm, rivaroxaban given 8.50am (1 <sup>st</sup> level)  PEG feed given 1.30pm-9.30am, rivaroxaban given 8.50pm (2 <sup>nd</sup> level)	Bolus PEG feed regime with Fortisip at 8am, 1pm and 6pm and Calogen at 3pm  Rivaroxaban given at 6pm	PEG feed given 12am to 2pm  Rivaroxaban given at 1.40pm
<b>Rivaroxaban plasma concentration** (ng/ml)</b>	<20 (14 hours post dose)  61 (3 hours post dose)	64 (3 hours post dose)	76 (3.5 hours post dose)
<b>Number of doses of rivaroxaban recieved prior to level</b>	14	8	2
<b>Outcome</b>	Switched to warfarin	Switched to apixaban and transferred to local hospital for rehabilitation	Switched to apixaban with an adequate trough concentration achieved (65 ng/ml)

\*calculated using Cockcroft - Gault equation

\*\* STA-liquid anti-Xa assay® (Diagnostica Stago, France), with appropriate rivaroxaban calibrators and controls

Following ingestion of rivaroxaban, the mean plasma concentrations for the 20mg dose of rivaroxaban in the AF population at 3 hours is reported to be 246 ng/mL (5<sup>th</sup>-95<sup>th</sup> percentile: 172–361) [Mueck *et al.*, 2013]. As can be seen from table 1, the concentrations achieved by these patients are significantly lower than what one might expect.

The administration of rivaroxaban via gastric tubes is recommended by the manufacturers of the agent, based on work in 55 healthy adults, by Moore and colleagues [2014]. This study reports that when rivaroxaban is crushed and administered via a NG tube, a similar relative bioavailability

compared to a whole tablet ingested is achieved. However, a report from Japan, where licensed doses of rivaroxaban are lower than those recommended elsewhere world-wide, reports that Japanese stroke patients receiving crushed rivaroxaban tablets had significantly lower rivaroxaban concentrations, than those stroke patients receiving the whole tablets at the equivalent dose [Okata *et al.*, 2014].

When tablets are crushed, there is always the possibility that some may be lost in the crushing device, adsorbed to the feeding tube and lost in its transfer from the crushing device to the feeding tube. Furthermore, rivaroxaban has poor water solubility and does not easily suspend in water, therefore making a suitable liquid preparation on the ward environment would be challenging. Our limited experience and that from Japan does suggest that significantly lower rivaroxaban concentrations are observed, when tablets are crushed and administered by a feeding tube in clinical practice and it would be sensible to assay rivaroxaban plasma concentrations when used in scenarios like this.

Other direct oral anticoagulants, whose absorption is not dependent on food, may result in adequate plasma concentrations. . Indeed apixaban's absorption is not dependent on food and apixaban's manufacturers suggest that following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of water and delivered via a nasogastric tube, exposure is similar to exposure seen in clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose [SPC, 2016].

Switching from rivaroxaban to apixaban was the course of action taken in 2 of the 3 cases presented here, with an apixaban plasma concentration being measured in 1 patient and found to be adequate. Edoxaban has also shown similar exposure to that seen in healthy subjects receiving a single 60mg dose, when crushed, mixed with water and administered via a nasogastric tube [Duchin *et al* 2017]. Dabigatran cannot be administered via gastric tubes due to the significantly increased bioavailability of dabigatran if it is administered without the capsule shell. [SPC, 2018].

In conclusion, if rivaroxaban is administered via a gastric tube, it would be prudent to measure plasma concentrations to ensure adequate exposure is being achieved. It may be possible to achieve adequate rivaroxaban plasma concentrations when administered via gastric tube providing the rivaroxaban SPC instructions are followed to the letter. As our experience has shown this may be difficult to achieve in clinical practice. If adequate DOAC concentrations are not achieved through

crushing process, then a vitamin K antagonist like warfarin with INR monitoring does remain a suitable option.

## References

1. Medicines.org.uk 2017. Rivaroxaban 20mg tablets-Summary of Product Characteristics (SPC) - (eMC). [online] , available at <https://www.medicines.org.uk/emc/product/2793> [accessed 23/5/2018]
2. Mueck W, Schwers S & Stampfuss J. (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. *Thrombosis Journal* 11:10, 1-17
3. Medicines.org.uk 2018. Dabigatran 150mg hard capsules-Summary of Product Characteristics (SPC) - (eMC). [online] , available at [www.medicines.org.uk/emc/product/4703](http://www.medicines.org.uk/emc/product/4703) [accessed 23/5/2018] Moore KT, Krook MA, Vaidyanathan S, Sarich TC, Damaraju CV & Fields LE. (2014) Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. *Clinical Pharmacology in Drug Development* 3(4) 321-327
4. Okata T, Toyoda K, Okamoto A, Miyata T, Nagatsuka K & Minematsu K. (2014) Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. *PLoS ONE* 9 (11): e113641.doi:10.1371/journal.pone.0113641
5. Medicines.org.uk 2017. Apixaban 5mg tablets-Summary of Product Characteristics (SPC) - (eMC). [online] , available at [www.medicines.org.uk/emc/product/2878](http://www.medicines.org.uk/emc/product/2878) [accessed 23/5/2018]
6. An Open label cross over study of the pharmacokinetics of the 60mg edoxaban tablet crushed and administered either via nasogastric tube or in apple puree in healthy adults. Duccin K, Duggal A, Atiee G, Kidokoro M, Takatani T, Shipitofsky N, He L, Zhang G, Kakkar T (2018) *Clinical Pharmacokinetics* 57:2, 221

**Author for correspondence:**

Rosalind Byrne

Department of Haematological Medicine

King's College Hospital

London

SE5 9RS

Email: rosalind.byrne@nhs.net

Tel: 020 3299 3159

Fax: 020 3299 4689

**Keywords:** absorption, apixaban, feeding tubes, rivaroxaban, stroke

**Conflicts of Interests**

The authors have no relevant conflicts of interest to declare.